- Home | GSK US
Meet Ben: From Drug Discovery to Leading Innovation in Boston Ben Schwartz, VP of Oncology, shares his 20-year GSK journey, from drug discovery to leading research
- Search jobs - GSK US
Life at GSK We are transforming our culture to create an environment where individuals and teams are inspired to be ambitious for patients
- Vaccines | GSK US
The vaccines in our portfolio have been helping to protect people from serious disease for well over 100 years, with our Marietta, PA site dedicated to smallpox vaccine production since 1882 Today, our vaccines continue to make an impact for society by tackling some of the world’s most devastating diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and
- GSK invests $120 million in next-generation US biopharmaceutical . . .
GSK today announced a $120 million investment to expand its manufacturing facility in Upper Merion, Pennsylvania that will support the delivery of the company’s pipeline, bringing new medicines for cancer and other specialty diseases to patients faster
- Careers | GSK US
At GSK, we unite science, technology and talent to get ahead of disease together We aim to positively impact the health of 2 5 billion people by the end of the decade, as a successful, growing company where people can thrive
- Press release - us. gsk. com
With a heritage dating back to 1882, Marietta was GSK’s first site to continuously operate in the United States Packing approximately 100 million doses annually for the US market and supplying 88 countries, Marietta is a critical link in the global GSK supply chain
- GSK begins shipping influenza vaccine doses for the 2025-26 flu season . . .
GSK has begun shipping trivalent flu vaccine doses to US healthcare providers and pharmacies for the 2025–26 flu season
- GSK announces cap of $35 per month on U. S. patient out-of-pocket costs . . .
GSK will share specific details closer to implementation Today’s announcement builds on GSK’s strong track record of increasing access and improving the affordability of its medicines, including an ongoing commitment to responsible pricing
|